Verrica Pharmaceuticals Inc. financial data

Symbol
VRCA on Nasdaq
Industry
Pharmaceutical Preparations
Location
10 North High Street, Suite 200, West Chester, PA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 410 % -69.8%
Quick Ratio 9.59 %
Debt-to-equity 491 % +5019%
Return On Equity -692 % -1413%
Return On Assets -117 % -181%
Operating Margin -581 % -113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.7M shares +1.44%
Common Stock, Shares, Outstanding 42.5M shares +1.44%
Entity Public Float 152M USD +384%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 46.5M shares +1.28%
Weighted Average Number of Shares Outstanding, Diluted 46.5M shares +1.28%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 13.9M USD +61.6%
Cost of Revenue 700K USD
Research and Development Expense 21.3M USD -26.2%
General and Administrative Expense 17.4M USD -25.8%
Operating Income (Loss) -80.9M USD -245%
Nonoperating Income (Expense) -6.07M USD -14562%
Net Income (Loss) Attributable to Parent -86.9M USD -271%
Earnings Per Share, Basic -1.9 USD/shares -342%
Earnings Per Share, Diluted -1.9 USD/shares -342%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.9M USD -42.1%
Cash, Cash Equivalents, and Short-term Investments 39.5M USD -50.3%
Accounts Receivable, after Allowance for Credit Loss, Current 10M USD
Inventory, Net 2.7M USD
Assets, Current 47.3M USD -16.7%
Property, Plant and Equipment, Net 710K USD -80.7%
Operating Lease, Right-of-Use Asset 1.01M USD -22.7%
Other Assets, Noncurrent 453K USD +3.9%
Assets 52M USD -16.4%
Accounts Payable, Current 1.15M USD -44.1%
Employee-related Liabilities, Current 2.34M USD +109%
Liabilities, Current 20.1M USD +250%
Operating Lease, Liability, Noncurrent 744K USD -30.5%
Liabilities 65.3M USD +860%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -268M USD -48%
Stockholders' Equity Attributable to Parent -13.3M USD -124%
Liabilities and Equity 52M USD -16.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.9M USD -335%
Net Cash Provided by (Used in) Financing Activities -661K USD -102%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 42.6M shares +1.44%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.6M USD -180%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.9M USD -42.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.84M USD
Deferred Tax Assets, Valuation Allowance 53.7M USD +35.1%
Deferred Tax Assets, Gross 54.3M USD +35.3%
Operating Lease, Liability 1.08M USD -22%
Depreciation 100K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -67M USD -174%
Lessee, Operating Lease, Liability, to be Paid 1.18M USD -24.7%
Property, Plant and Equipment, Gross 1.91M USD -58.9%
Operating Lease, Liability, Current 332K USD +7.44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 366K USD -1.61%
Lessee, Operating Lease, Liability, to be Paid, Year One 372K USD -5.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 105K USD -44.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 247K USD
Deferred Tax Assets, Operating Loss Carryforwards 37.2M USD +24.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 247K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 621K USD +54.9%
Share-based Payment Arrangement, Expense 16M USD +207%
Interest Expense 8.65M USD +35938%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%